This brand name is authorized in Nigeria.
The drug OMEFAST PLUS contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
H1250JIK0A - CLARITHROMYCIN
|
|
Clarithromycin is a semi-synthetic derivative of erythromycin A. It exerts its antibacterial action by selectively binding to the 50s ribosomal sub-unit of susceptible bacteria preventing translocation of activated amino acids. It inhibits the intracellular protein synthesis of susceptible bacteria. |
|
2
|
UNII
KG60484QX9 - OMEPRAZOLE
|
|
Omeprazole, a racemic mixture of two enantiomers reduces gastric acid secretion through a highly targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. It is rapidly acting and provides control through reversible inhibition of gastric acid secretion with once daily dosing. |
|
3
|
UNII
033KF7V46H - TINIDAZOLE
|
|
Tinidazole is active against both protozoa and obligate anaerobic bacteria. The activity against protozoa involves Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia. The mode of action of tinidazole against anaerobic bacteria and protozoa involves penetration of the drug into the cell of the micro-organism and subsequent damage of DNA strands or inhibition of their synthesis. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| A4-6064 | Kit | Omefast Plus Combi Kit_ KIT 20 mg; 250 mg; 500 mg Combi Kit (2 + 2 + 2) x 7's | Solid Dosage Form. 6/4/2024 11:53:48 OMEFAST PLUS COMBI KIT CLARITHROMYCIN USP 250MG, OMEPRAZOLE BP 20MG & TINIDAZOLE BP 500MG A4-6064 COMBI KITS ORAL CLARITHROMYCIN USP 250MG, OMEPRAZOLE BP 20MG & TINIDAZOLE BP 500MG CLARITHROMYCIN USP 250MG, OMEPRAZOLE BP 20MG & TINIDAZOLE BP 500MG COMBI KIT 7X(2+2+2) (Measurement Unit: MILIGRAM (MG)) OTC GREENLIFE PHARMACEUTICALS LTD. 35A ASSOCIATION AVENUE, ILUPEJU, LAGOS. M/S MCW HEALTHCARE(P) LTD 286, 287-A, 287-B, SECTOR-E, INDUSTRIAL AREA, SANWER ROAD, INDORE (M.P), INDIA, INDIA INDIA 28/11/2022 27/11/2027 No A02BD | 28/11/2022 |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| A02BC51 | A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BC Proton pump inhibitors | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | A4-6064 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.